Statements (24)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:chemical_compound
|
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:ATCCode |
L01EA01
|
| gptkbp:CASNumber |
gptkb:112809-51-5
|
| gptkbp:commonName |
gptkb:Imatinib
|
| gptkbp:developedBy |
gptkb:Novartis
|
| gptkbp:hasMolecularFormula |
C29H31N7O
|
| gptkbp:hasSMILES |
CC1=CC(=CC=C1)NC2=NC=NC(=C2)C3=CN=CC=C3
|
| gptkbp:hasUNII |
8C8O2UF0ZV
|
| https://www.w3.org/2000/01/rdf-schema#label |
112809-51-5
|
| gptkbp:isUsedToTreat |
gptkb:chronic_myeloid_leukemia
gastrointestinal stromal tumors |
| gptkbp:IUPACName |
gptkb:4-[(4-methylpiperazin-1-yl)methyl]-N-[4-methyl-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]phenyl]benzamide
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:marketedAs |
gptkb:Gleevec
gptkb:Glivec |
| gptkbp:molecularWeight |
493.6 g/mol
|
| gptkbp:PubChem_CID |
gptkb:CHEMBL941
gptkb:DB00619 5291 |
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:usedFor |
antineoplastic agent
|
| gptkbp:bfsParent |
gptkb:Femara
|
| gptkbp:bfsLayer |
5
|